Tuesday, August 9, 2016
ClinicalRM will again deploy its boots-on-the-ground approach to fighting Ebola Virus Disease (EVD) with an expanded access protocol for ZMapp, an investigational treatment for EVD, in Africa and the U.S.
Velocity Fund Partners, a Pittsburgh private equity company, has announced the acquisition of the Philadelphia clinical CRO Indipharm and its relaunch as InClinica. Financial terms were not disclosed.
The Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites, has announced an expanded relationship with inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market.
Profil Institute for Clinical Research, a science-driven CRO focused exclusively on metabolic diseases, has announced a strategic master services agreement with Shenzhen HighTide Biopharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical.
Quintiles, a provider of product development and integrated healthcare services, and DaVita Clinical Research, a wholly-owned subsidiary of DaVita HealthCare Partners, a leader in kidney care, have announced a global strategic alliance. The alliance combines DaVita’s clinical care and expansive footprint of research sites with Quintiles’ operational delivery and therapeutic expertise in clinical trials.
inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, announced that Advent International, one of the largest and most experienced global private equity investors, has joined Thomas H. Lee Partners (THL) as an equal equity owner of inVentiv Health.
INC Research Holdings, a global phase I to IV CRO, has launched the company’s Vaccine Catalyst Site network as part of its Catalyst program introduced earlier this year to strengthen collaborations with clinical research sites worldwide, ultimately enhancing patient focus and optimizing study delivery to drive improved predictability and increased efficiency for customers. INC selected 40 high-performing clinical research sites to participate in the initial launch of its Vaccine Catalyst Site network, which was formed to respond to the rapid growth and strong pipeline of vaccine studies.
Bioclinica, a provider of specialized technology-enabled services supporting clinical trials, has acquired Compass Research, a U.S. clinical research site network with direct access to a number of specialized populations with neurodegenerative disorders and other diseases found in aging demographics.
A recent survey by Worldwide Clinical Trials reveals that 62% of respondents are more likely to engage a CRO partner for clinical research than they were five years ago, demonstrating the increasingly vital role that CROs are playing in modern drug development, and the importance of partnering with a CRO that offers medical and scientific expertise.